Read the latest positive news, breakthroughs, and inspiring stories about moderna, curated daily by BrightWire.
A breakthrough cancer treatment from Moderna could help millions of patients in the next decade. The personalized vaccine showed remarkable results in melanoma patients and is being tested for lung, bladder, and kidney cancers too.
A personalized cancer vaccine from Moderna just aced its phase 3 trial for melanoma patients, marking a potential first for mRNA technology in cancer treatment. The same company that brought us a COVID vaccine in record time could soon revolutionize how we fight cancer.
After a century of failed attempts, a personalized mRNA cancer vaccine has successfully completed late-stage trials in melanoma patients. The treatment trains each person's immune system to fight their unique tumor mutations.
A new personalized cancer vaccine using mRNA technology has shown remarkable results in preventing melanoma from returning after surgery. The breakthrough could open doors for similar treatments across dozens of other cancers.
A groundbreaking cancer vaccine from Moderna and Merck reduced the chances of melanoma returning after surgery in a major trial with over 1,100 patients. Even the company's own executives didn't believe it would work.
A personalized cancer vaccine from Moderna and Merck just succeeded in its first large-scale trial, cutting melanoma recurrence rates and bringing hope to thousands. The breakthrough could transform how we treat cancer within the next year.
A groundbreaking mRNA cancer vaccine has shown promising results in preventing melanoma from returning after surgery, marking the first successful late-stage trial of its kind. The same technology behind COVID-19 vaccines could soon help thousands of cancer patients stay disease-free.
A personalized cancer vaccine using mRNA technology just helped melanoma patients live longer without their cancer returning. The breakthrough treatment could become the first of its kind approved for cancer care.
A personalized cancer treatment using the same technology behind COVID vaccines just proved it can significantly reduce melanoma recurrence in the largest trial of its kind. Experts are calling it a breakthrough that could transform how we fight cancer.
A personalized mRNA cancer vaccine developed by Moderna and Merck has shown remarkable success in preventing melanoma from returning. The breakthrough sent Moderna's stock soaring 90% and offers new hope for treating cancer beyond COVID vaccines.
A personalized cancer vaccine using the same mRNA technology that powered COVID vaccines just proved it works in major trials, tripling Moderna's stock price in one day. For melanoma patients, it's the breakthrough they've been waiting for.
A personalized mRNA cancer vaccine from Merck and Moderna has succeeded in Phase 3 trials, marking a major breakthrough in immunotherapy. The treatment, called intismeran autogene, tailors cancer-fighting instructions to each patient's unique tumor.